Evidence for a dopaminergic activity of methysergide in humans.
The acute administration of 2 mg of methysergide significantly reduced plasma prolactin levels in nine normal subjects and in seven hyperprolactinaemic patients. The prolactin lowering effect of this drug was abolished by sulpiride. Morever methysergide lowered plasma GH levels in four out of nine acromegalic patients, who were also responsive to a dopaminergic drug such as bromocriptine. Although methysergide did not significantly blunt the TRH-induced prolactin release, our data suggest that this drug may affect GH and prolactin release through a dopaminergic mechanism of action. This effect should be taken into account when methysergide is employed as antiserotoninergic drug in neuroendocrinological studies.
D000172:Acromegaly / Q000188:drug therapy; D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008784:Methysergide / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D011954:Receptors, Dopamine / Q000187:drug effects*; D013469:Sulpiride / Q000494:pharmacology
D011954:Receptors, Dopamine; D013469:Sulpiride; D011388:Prolactin; D013006:Growth Hormone; D008784:Methysergide